Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$45213 of $63500 - as of 2024-10-31
71%
ADxS.org Logo
ADxS.org Logo
Search Donations Addresses Recent changes ADHS-Forum Deutsche Version
Register

Already have an account? Login

Header Image
Centanafadine for ADHD

Sitemap

The ADxS.org project
Abstract from ADxS.org
Symptoms
Consequences of ADHD
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment: Guide and Effect size
Treatment: Medication for ADHD
Treatment: Medication for ADHD - Overview
Choice of medication for ADHD or ADHD with comorbidity
Dosing of medication for ADHD
Suitable medication for ADHD
Experimental medication for ADHD
Sleep disorder-related medication for ADHD
Appetite-enhancing medication for ADHD
Medication for ADHD in development
Less suitable medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effect in ADHD
Non-drug treatment
Addresses
This and that about ADHD
Tests and surveys
Forum

Centanafadine for ADHD

Previous page Next page

Centanafadine is a

  • Noradrenaline reuptake inhibitors
  • Dopamine reuptake inhibitors
  • Serotonin reuptake inhibitors (weak)

Two randomized, double-blind, placebo-controlled, parallel-group phase 3 studies were conducted in adults with ADHD using 200 mg/d or 400 mg/d centanafadine sustained-release tablets.12
At Day 42, both studies showed improvements in AISRS total score compared to placebo with Effect sizes of -0.28 for 200 mg/d and -0.24 for 400 mg/d in Study 1 and -0.37 for 200 mg/d and -0.40 for 400 mg/d in Study 2.

Centanafadine was well tolerated and the overall rate of adverse events was low, but dose-dependent.

Centanafadine is currently being studied in several clinical trials for its efficacy and safety in children and adolescents with ADHD (NCT05279313, NCT05428033, NCT05257265).3

  1. Adler, Adams, Madera-McDonough, Kohegyi, Hobart, Chang D, Angelicola, McQuade, Liebowitz (2022): Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials. J Clin Psychopharmacol. 2022 Jun 2. doi: 10.1097/JCP.0000000000001575. PMID: 35652746. ↥

  2. Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE (2020): Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies. Neuropsychiatr Dis Treat. 2020 Jun 8;16:1411-1426. doi: 10.2147/NDT.S242084. PMID: 32606695; PMCID: PMC7292254. ↥

  3. Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB (2022): Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022 Nov 17;13:1066988. doi: 10.3389/fphar.2022.1066988. PMID: 36467081; PMCID: PMC9713849. ↥

Previous page Next page